UK silent heart attack market is estimated to grow considerably at a CAGR of around 6.8% during the forecast period. UK has one of the finest healthcare systems in the EU region which enables it to provide quality healthcare to the individual citizens. According to British Heart Foundation, more than 7 million people are living with one or the other type of heart diseases in UK. Lingering heart diseases put economic burden to the UK government which includes cost of premature deaths, lost productivity, hospital stay and prescriptions which are estimated to be around $50 billion annually. According to the British Heart Foundation, 0.17 million heart attacks occur every year in UK. In which 0.11 million men and 0.06 million women lose their life annually in UK due to heart attack each year.

UK silent heart attack market is segmented into diagnosis, treatment, and end-user. Based on the diagnosis, the market is segmented into an electrocardiography (ECG), chest x-ray, computed tomography (CT Scan), echocardiography, and others (blood test). Based on treatment, the market is segmented into medication and surgery. Based on end-user, the market is segmented into hospitals & clinics and ambulatory surgical centers (ASCs). Significant availability of hospitals coupled with the presence of skilled professionals with different specialties in hospitals is contributing to the treatment if silent heart attack in hospitals and clinics. Therefore, hospitals and clinics are mainly preferred for the treatment of CVD conditions.

The companies which are contributing to the growth of the UK silent heart attack market include AstraZeneca PLC, Bayer AG, Siemens AG, F. Hoffmann-La Roche Ltd., Boehringer Ingelheim GmbH, and GlaxoSmithKline Plc. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups, and technological advancements to stay competitive in the market. 

Research Methodology

The market study of the UK silent heart attack market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include

• Financial reports of companies involved in the market.
• Whitepapers, research-papers, and news blogs.
• Company websites and their product catalog.

The report provides an in-depth analysis of market size, various services offered by the players, and market opportunity. The report will serve as a source for 360-degree analysis of the market delivering insights for making better business decisions.

Market Segmentation

1. UK Silent heart attack Market Research and Analysis by Diagnosis
2. UK Silent heart attack Market Research and Analysis by Treatment
3. UK Silent heart attack Market Research and Analysis by End-Users

The Report Covers

• Comprehensive research methodology of the UK silent heart attack market.
• This report also includes a detailed and extensive market overview with key analyst insights.
• An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
• Analysis of regional regulations and other government policies impacting the UK silent heart attack market.
• Insights about market determinants which are stimulating the UK silent heart attack market.
• Detailed and extensive market segments with regional distribution of forecasted revenues.
• Extensive profiles and recent developments of market players.